Polarityte Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Polarityte Inc (PTE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Polarityte Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 14M vs -M combined for its competitors (100.0% combined share).
- Structure: Polarityte Inc operates in the following segments: Contract Services, Regenerative Medicine.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Polarityte Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Polarityte Inc | - | - | - | No |
| Competitors combined (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PTE Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Fibrobiologics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Polarityte Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Polarityte Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Polarityte Inc |
1.76 | 13.90 |
 Fibrobiologics Inc |
6.07 | - |
| SUBTOTAL | 7.83 | 13.90 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Polarityte Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Polarityte Inc's Competitors Named by the Company
Competitive relationships identified from Polarityte Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Fibrobiologics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Polarityte Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Polarityte Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Polarityte Inc | Contract Services 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Polarityte Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Polarityte Inc | 2 | - | - |
| Fibrobiologics Inc | 6 | - | -1,209,267 |
| PEERS TOTAL | 6 | - | -1,209,267 |
Polarityte Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | -0.8x | 16.7x | -17.5x |
| P/B | 0.3x | 5.1x | -4.8x |
| Return on Equity | -50.31 % | industry aggregate | -62.55 % |
| Return on Invested Capital | -48.23 % | -11.27 % (avg) | -36.96 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Polarityte Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -65.22 % | -76.03 % | - | - | -500.00 % | 79.16 % | -7.13 % | - |
| Operating Margin | -64.12 % | -94.75 % | - | - | 6.77 % | - | - | - |
| Return on Invested Capital | -58.78 % | -21.41 % | -8,967.14 % | - | -78.68 % | -61.53 % | -53.08 % | -55.29 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Polarityte Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 62.6 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Polarityte Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Polarityte Inc | 5.16 | 6.03 | 0.00 |
| Fibrobiologics Inc | 1.18 | 1.62 | 0.37 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Polarityte Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Polarityte Inc | Q1 2023 | - | - |
| Fibrobiologics Inc | Q2 2026 | - | - |
| PEERS TOTAL | - | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Polarityte Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Polarityte Inc | Q1 2023 | - | - |
| Fibrobiologics Inc | Q2 2026 | - | - |
Polarityte Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Polarityte Inc | - | - | - |
| Fibrobiologics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Polarityte Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Polarityte Inc | - | 0.13 |
| Fibrobiologics Inc | - | - |
| PEERS AVERAGE | - | 0.56 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.